This is a registry record, not a result. A trial being listed, recruiting or completed says nothing by itself about whether the compound works or is safe.
| Registry number | NCT05582096 |
|---|---|
| Status | Completed |
| Phase | Phase 1 |
| Sponsor | Eli Lilly and Company |
| Enrollment | 38 participants |
| Design | Interventional, Randomized, Parallel, Masking: Double |
| Conditions | Overweight; Obesity |
| Interventions | LY3457263; Tirzepatide; Placebo |
| Start | Nov 11, 2022 |
| Primary completion | Jun 8, 2023 |
| Study completion | Jun 8, 2023 |
| Results posted | Not yet |
| Registry last updated | Jul 18, 2023 |
Compounds on this site that cite this trial
What the registry says the trial is about
The main purpose of this study is to evaluate the safety and tolerability of LY3457263 when administered in combination with tirzepatitide in overweight or obese participants. The study will also evaluate how much of LY3457263 gets into the blood stream and how long it takes the body to remove it in overweight or obese participants. The study will last up to approximately 11 weeks.
Primary outcomes
These are what the trial was designed to measure first. They are registered in advance, which is what makes a later result checkable.
| Outcome measure | Time frame |
|---|---|
| Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration | Baseline up to 11 weeks |
1 secondary outcome also registered. See the registry record for the full list.
Source: ClinicalTrials.gov (U.S. National Library of Medicine). Last checked against the registry on Oct 3, 2026. See the trial changes feed for what has changed recently.
